| Taral R Sharma, MD | |
|
120 Pelham Ln, Anderson, SC 29621-3335 | |
| (864) 844-9432 | |
| (864) 844-9430 |
| Full Name | Taral R Sharma |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 19 Years |
| Location | 120 Pelham Ln, Anderson, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710121009 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 35458 (South Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Taral Sharma Md Pc | 0244568152 | 13 |
News Archive
Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB® could play a key role in treating open angle glaucoma (OAG), a neurodegenerative disease that affects over 70 million people worldwide and causes irreversible blindness.
In adults, certain regions of the brain's visual cortex respond preferentially to specific types of input, such as faces or objects - but how and when those preferences arise has long puzzled neuroscientists.
The U.S. Food and Drug Administration today announced a new initiative to ensure that caregivers and patients safely use complex medical devices in the home.
Researchers at the Johns Hopkins Kimmel Cancer Center say they have developed a system that uses transformed human stem cells to speed up screening of existing drugs that might work against rare brain and other cancers.
› Verified 4 days ago
| Entity Name | Prisma Health University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295763217 PECOS PAC ID: 8325950983 Enrollment ID: O20031103000238 |
News Archive
Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB® could play a key role in treating open angle glaucoma (OAG), a neurodegenerative disease that affects over 70 million people worldwide and causes irreversible blindness.
In adults, certain regions of the brain's visual cortex respond preferentially to specific types of input, such as faces or objects - but how and when those preferences arise has long puzzled neuroscientists.
The U.S. Food and Drug Administration today announced a new initiative to ensure that caregivers and patients safely use complex medical devices in the home.
Researchers at the Johns Hopkins Kimmel Cancer Center say they have developed a system that uses transformed human stem cells to speed up screening of existing drugs that might work against rare brain and other cancers.
› Verified 4 days ago
| Entity Name | South Carolina Dept Of Mental Health Accounting Office |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376595041 PECOS PAC ID: 9032021175 Enrollment ID: O20031105000630 |
News Archive
Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB® could play a key role in treating open angle glaucoma (OAG), a neurodegenerative disease that affects over 70 million people worldwide and causes irreversible blindness.
In adults, certain regions of the brain's visual cortex respond preferentially to specific types of input, such as faces or objects - but how and when those preferences arise has long puzzled neuroscientists.
The U.S. Food and Drug Administration today announced a new initiative to ensure that caregivers and patients safely use complex medical devices in the home.
Researchers at the Johns Hopkins Kimmel Cancer Center say they have developed a system that uses transformed human stem cells to speed up screening of existing drugs that might work against rare brain and other cancers.
› Verified 4 days ago
| Entity Name | South Carolina Dept Of Mental Health Accounting Office |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619995370 PECOS PAC ID: 9032021175 Enrollment ID: O20040624000139 |
News Archive
Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB® could play a key role in treating open angle glaucoma (OAG), a neurodegenerative disease that affects over 70 million people worldwide and causes irreversible blindness.
In adults, certain regions of the brain's visual cortex respond preferentially to specific types of input, such as faces or objects - but how and when those preferences arise has long puzzled neuroscientists.
The U.S. Food and Drug Administration today announced a new initiative to ensure that caregivers and patients safely use complex medical devices in the home.
Researchers at the Johns Hopkins Kimmel Cancer Center say they have developed a system that uses transformed human stem cells to speed up screening of existing drugs that might work against rare brain and other cancers.
› Verified 4 days ago
| Entity Name | Chestnut Hill Mental Health Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386603793 PECOS PAC ID: 0648259887 Enrollment ID: O20040720000395 |
News Archive
Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB® could play a key role in treating open angle glaucoma (OAG), a neurodegenerative disease that affects over 70 million people worldwide and causes irreversible blindness.
In adults, certain regions of the brain's visual cortex respond preferentially to specific types of input, such as faces or objects - but how and when those preferences arise has long puzzled neuroscientists.
The U.S. Food and Drug Administration today announced a new initiative to ensure that caregivers and patients safely use complex medical devices in the home.
Researchers at the Johns Hopkins Kimmel Cancer Center say they have developed a system that uses transformed human stem cells to speed up screening of existing drugs that might work against rare brain and other cancers.
› Verified 4 days ago
| Entity Name | Taral Sharma Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477112597 PECOS PAC ID: 0244568152 Enrollment ID: O20190829002356 |
News Archive
Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB® could play a key role in treating open angle glaucoma (OAG), a neurodegenerative disease that affects over 70 million people worldwide and causes irreversible blindness.
In adults, certain regions of the brain's visual cortex respond preferentially to specific types of input, such as faces or objects - but how and when those preferences arise has long puzzled neuroscientists.
The U.S. Food and Drug Administration today announced a new initiative to ensure that caregivers and patients safely use complex medical devices in the home.
Researchers at the Johns Hopkins Kimmel Cancer Center say they have developed a system that uses transformed human stem cells to speed up screening of existing drugs that might work against rare brain and other cancers.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Taral R Sharma, MD 120 Pelham Ln, Anderson, SC 29621-3335 Ph: (864) 844-9432 | Taral R Sharma, MD 120 Pelham Ln, Anderson, SC 29621-3335 Ph: (864) 844-9432 |
News Archive
Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB® could play a key role in treating open angle glaucoma (OAG), a neurodegenerative disease that affects over 70 million people worldwide and causes irreversible blindness.
In adults, certain regions of the brain's visual cortex respond preferentially to specific types of input, such as faces or objects - but how and when those preferences arise has long puzzled neuroscientists.
The U.S. Food and Drug Administration today announced a new initiative to ensure that caregivers and patients safely use complex medical devices in the home.
Researchers at the Johns Hopkins Kimmel Cancer Center say they have developed a system that uses transformed human stem cells to speed up screening of existing drugs that might work against rare brain and other cancers.
› Verified 4 days ago
Urvi Shah, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 130 Highway 252, Anderson, SC 29621 Phone: 864-231-2600 | |
Abdalla Bamashmus, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 800 N Fant St, Anderson, SC 29621 Phone: 864-512-1810 Fax: 864-512-1805 | |
Joseph M Mcelwee, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2000 E Greenville St, Suite 3700, Anderson, SC 29621 Phone: 864-512-1475 Fax: 864-512-1930 | |
John H Purcell, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 130 Hwy 252, Anderson, SC 29622 Phone: 803-898-8405 | |
Sam Harry Ross, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 130 Highway 252, Anderson, SC 29621 Phone: 803-898-8405 | |
Dr. Violeta Nistor, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 130 Sc-252, Anderson, SC 29621 Phone: 864-231-2600 | |
Raymond Kimball, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 130 Highway 252, Anderson, SC 29621 Phone: 803-898-8405 |